Figure 8. The Influence of MβCD on the Expression of CD19 and CD20 As Well As on Rituximab-Mediated CDC Against Primary Human Lymphoma Cells.
Primary human CD20+ B cell lymphoma cells—mantle cell lymphomas in (A–C), and small B cell lymphoma in (D)—were incubated with either diluent or MβCD (10 mg/ml) for 30 min. Then, 1 × 106 cells/ml were incubated with saturating amounts of FITC-conjugated anti-CD20 mAb (B9E9, left graphs), PE-conjugated anti-CD19 mAb (center graphs), or IgG1 (isotype control) for 30 min at room temperature in the dark. For the rituximab-mediated CDC, human CD20+ B cell lymphoma cells were incubated with either diluent or 10 mg/ml MβCD for 30 min. Then, equal numbers of cells (1 × 105/well) were incubated for 60 min with 400 μg/ml rituximab in the presence of 10% human AB serum as a complement source. Cell viability was measured in a MTT assay. The survival of cells is presented as percentage of corresponding diluent- or MβCD-pretreated cells without rituximab (right graphs). *p = 0.032 for (A), p < 0.001 for (B) and (C), and p = 0.041 for (D) (two-way Student's t-test) as compared with controls.